The Robotic Surgery Market is growing at CAGR of 11.9%.
Robotic surgery is a type of minimally invasive surgical procedure that is done using robotic systems. It allows doctors to perform many types of complex procedures with more precision, flexibility, and control than conventional techniques.
In the last few years, minimally-invasive robotic-assisted surgery has been gaining huge popularity among the population as it offers umpteen benefits, including shorter hospitalization, reduced pain, and discomfort, faster recovery time, smaller incision, high precision level, improved reliability reduced blood loss and minimal scarring. For instance, Westchester Medical Center reported a 70% drop-in Intensive Care Unit C. diff with the use of Xenex Robots. Moreover, it also offers greater visualization, enhanced dexterity, and greater precision to surgeons. Therefore, the adoption of minimally invasive surgeries has augmented among end-users and will continue the same during the forecast period.
Report Metric | Details |
---|---|
Base Year | 2017 |
Study Period | 2016-2026 |
Forecast Period | 2023-2031 |
CAGR | 11.9% |
Market Size | |
Fastest Growing Market | Europe |
Largest Market | North America |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Geographies Covered |
|
Increasing patient pool suffering from cardiological, urological, neurological, and gynecological disorders is creating a huge demand for advanced treatment options. The major centers have adopted the da Vinci Surgical System for performing robotic heart surgeries, and have registered excellent results. The types of cardiac surgeries performed by robotic systems are mitral valve, repair or replacement, atrial septum defect closure, tricuspid valve repair, maze procedure to treat atrial fibrillation, and coronary artery bypass.
Currently, emerging nanobots are being investigated for the treatment of unclogging arteries. The other advances in cardiovascular surgery include catheter-based robots, robot-based valves, better operative techniques, smaller instruments, improved holographic 3D vision, nanotechnology, and faster and smaller computer circuits that enable a quicker transfer of data. For instance, Intuitive Surgical has developed da Vinci single-site technology that provides multiport and single-incision surgical procedures.
Moreover, increasing regulatory approvals will favor the growth of the global robotic surgery market. For instance, in 2019, Zimmer Biomet received clearance from the Food and Drug Administration (FDA) for the usage of its latest product ‘Rosa One Brain Application.’ The system allows surgical navigation and positioning for operations related to neurological body parts requiring extreme precision.
North America is dominating the global robotics surgery market and is likely to continue the same during the forecast period. The region is backed by the presence of robust healthcare infrastructure and a surge in the adoption of surgical robotic systems. Additionally, the increasing occurrence of cardiovascular cancer, gynecology, neurovascular, and other chronic disorders coupled with high adoption of advanced surgical treatments, increasing healthcare expenditure, and mounting robotic investments are adding fuel to the market growth. To attend to the situation, the leading players are actively working to develop advanced robots to enable precision surgical procedures is boosting the market growth to some extent.
Europe is second in the robotic surgery market on account of the rising adoption of robot-assisted surgical procedures. Europe has installed about 644 da Vinci xi robots across the healthcare sector, out of which, Spain and Portugal have around 12 da Vinci xi systems. The market is majorly driven by the initiatives taken by the European Association of Urology. For instance, recently, it launched the EAU Robotic Urology Section (ERUS), a scientific platform for urologists involved in the cutting-edge robotic surgery, which is further boosting the market growth in the urology sector. Similarly, the SAFROS Project by the European Commission is focused on providing patient safety, lesser complications, and shorter hospital stays through robot-assisted procedures.
Asia-Pacific is grabbing the highest shares in the robotic surgery market. This can be attributed to the rapidly developing infrastructure, rising investment in the healthcare sector, the emergence of private healthcare providers, increasing healthcare spending, and rising number of emerging players. The region is housing a major geriatric population susceptible to a number of diseases and ailments, which is further driving the demand for advanced medical technologies. Additionally, China, Japan, Singapore, Thailand, and Korea are joining forces to develop advanced medical robotics technologies, which is further adding fuel to the market growth. As per the South China Morning Post-publication, to date, the da Vinci system has been used in over 60,000 operations in China.
The Chinese government is taking initiatives to reduce the dependence on foreign technology and is encouraging the players to invest and develop advanced robotic systems for the same. Currently, SS Innovations is developing a modular and affordable robotic surgical system equipped with complex motion control technology. Similarly, Beijing Jishuitan Hospital and Beijing Tinavi Medical Technologies collaboratively developed ‘The TiRobot system,’ which uses robotics technology to create surgical pathways based on the 3-D scans. Lastly, Shenyang Siasun Robot and Automation is entering the arena with its product, named Medical-Healthcare Robot BU for operating on tumors, which is further boosting the market growth. Whereas, Japan has developed EMARO, a cost-effective endoscopic robot that facilitates surgeons’ hands-free control and improves visualization inside a patient’s body with 3 movable cameras.
The Thai government is heavily investing in the robotic surgery market since 2017. The first-ever robotic-assisted surgery was conducted in Bangkok's Ramathibodi Hospital. The Thailand Board of Investment is also providing incentives to facilitate the manufacturing of automation equipment and high-risk medical devices and assembly of robots. For instance, Bangkok-based CT Asia Robotics developed Dinsow, BUMBEE, and ROBODOCTOR, a remote diagnostic system.
Recently, Curexo invested about USD 9.7 milling in Hyundai Heavy Industries for its medical robotics division. Since then, it has created Robodoc that enables surgeons to perform knee and hip replacement surgeries using 3-D computer imaging. Similarly, Meere Co. developed Revo-i, a robot for laparoscopic surgeries. In Singapore, the development of robotics technologies, including SensibleTAB and SensibleSTEP for arm and leg injuries and practice movements, is boosting the market growth. Currently, EndoMaste, a robotics startup, is developing a tiny robotic endoscope to remove gastrointestinal tumors.
In the Middle East and Africa, around 44 robotic da Vinci Surgical Systems have been installed in Saudi Arabia (KSA), Qatar, the UAE, Kuwait, and Lebanon. The rising occurrence of chronic diseases, increasing geriatric population, complexity of surgical procedures, and growing preference towards minimally invasive surgeries (MIS) with more precision and flexibility is boosting the market growth. In addition, shifting trend towards automation in the healthcare sector is further propelling the market growth. Whereas, in Africa, high cost for the installation of robotic devices, the dearth of trained professionals, low healthcare spending, lack of hospitals proving robotic surgeries, and underdeveloped healthcare infrastructure are limiting the market growth to some extent.
The global robotic surgery market is segmented into applications and End-uses. The application segment is further sectored into orthopedic, neurology, urology, gynecology, general surgery, and others. The orthopedic segment is expected to grow at a lucrative rate over the forecast period. The rise in the number of orthopedic surgeries is the key factor driving the application of surgical robots in orthopedics. As per the Wolters Kluwer Journal, in the U.S. alone, about 700,000 knee procedures are performed every year using a surgical robot, which is further boosting the market growth.
Surgical robots are extensively used in shoulder arthroscopy, hip arthroscopy, total hip replacement, placement of pedicle screws, trauma, and general orthopedics as it eliminates the chances of human error. For instance, Mako Surgical, the Michigan based orthopedic device, recorded nearly 76,900 knee and hip replacement procedures in 2018 and has placed around 650 Mako robots across the globe. In line with the growing demand, the leading players in the market are actively working to develop innovative products and are engaging in mergers, collaborations, and acquisitions for the same. For instance, in January 2019, Zimmer Biomet received FDA clearance for the ROSA ONE Spine, a surgical navigation system that helps surgeons perform minimally invasive and complex spine procedures. The ROSA knee platform includes 3D pre-operative planning tools, which offers real-time data on tissue and bone anatomy during procedures. Recently, Medtronic, Smith & Nephew, and Johnson & Johnson acquired Orthotaxy, a French robotic-assisted surgery company.
The End-use segment is further sectored into hospitals, ambulatory surgical centers, and others. The hospital segment is anticipated to grab the largest share in the robotic surgery market and is expected to grow with the highest CAGR during the forecast period. This can be accredited to the increasing investments in the healthcare sector, rising adoption of surgical robots for performing various types of surgical procedures, the surge in the occurrence of chronic ailments and trauma incidences, and the availability of reimbursement policies for surgical procedures.
Eminent industry players active in the surgical robot’s market include Accuray, Globus Medical, Hansen Medical, Mazor Robotics, Omni, Stryker, Think Surgical, Intuitive Surgical Inc., Johnson & Johnson Services Inc., Medtronic Plc, Smith & Nephew Plc, Stryker Corp., and Zimmer Biomet Holdings Inc.